Name: | moxifloxacin |
---|---|
PubChem Compound ID: | 101526 |
Molecular formula: | C21H25ClFN3O4 |
Molecular weight: | 437.892 g/mol |
Synonyms: |
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, monohydrochloride; Izilox; Vegamox; BAY 12-8039; Moxifloxacin hydrochloride [USAN]; Moxiflocacin hydrochloride; Moxifloxacin hydrochloride; 186826-86-8; Actira; LS-173737.
show more » |
Name: | moxifloxacin |
---|---|
Name (isomeric): | DB00218 |
Drug Type: | small molecule |
Synonyms: |
Moxifloxacin hydrochloride; Moxifloxacin HCl; BAY 12-8039
|
Brand: | Avelox I.V., Avelox, Vigamox |
Category: | Anti-Bacterial Agents, Anti-Infective Agents, Quinolones |
CAS number: | 354812-41-2 |
Indication: | For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye). |
---|---|
Pharmacology: |
Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus...
show more » |
Mechanism of Action: |
The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during ...
show more » |
Absorption: | Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption. |
Protein binding: | 50% bound to serum proteins, independent of drug concentration. |
Biotransformation: | Approximately 52% or oral or intravenous dose is metabolized via glucuronide and sulphate conjugation. The cytochrome P450 system is not involved in metabolism. The sulphate conjugate accounts for 38% of the dose, and the glucuronide conjugate accounts for 14% of the dose. |
Route of elimination: | Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces). |
Half Life: | 11.5-15.6 hours (single dose, oral) |
Clearance: | 12 +/- 2 L/hr |
Toxicity: | Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg. |
Affected organisms: | Enteric bacteria and other eubacteria |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|